Amy Burroughs Sells 68,749 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Amy Burroughs sold 68,749 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $37.07, for a total value of $2,548,525.43. Following the transaction, the chief executive officer owned 288,976 shares in the company, valued at approximately $10,712,340.32. The trade was a 19.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Terns Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ:TERN traded down $0.38 during midday trading on Friday, hitting $36.60. 1,918,829 shares of the stock traded hands, compared to its average volume of 2,519,463. The stock has a market capitalization of $3.30 billion, a PE ratio of -35.53 and a beta of -0.28. Terns Pharmaceuticals, Inc. has a one year low of $1.87 and a one year high of $48.26. The business’s 50 day moving average is $34.14 and its two-hundred day moving average is $16.58.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. As a group, sell-side analysts forecast that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. FNY Investment Advisers LLC bought a new stake in Terns Pharmaceuticals during the 4th quarter valued at about $80,000. Tema Etfs LLC acquired a new stake in shares of Terns Pharmaceuticals in the 4th quarter worth $414,000. SG Americas Securities LLC purchased a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $1,772,000. GAMMA Investing LLC increased its position in shares of Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after acquiring an additional 770 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Terns Pharmaceuticals by 90.6% in the third quarter. JPMorgan Chase & Co. now owns 682,708 shares of the company’s stock valued at $5,127,000 after purchasing an additional 324,502 shares during the period. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Wall Street Analyst Weigh In

TERN has been the topic of several research reports. BMO Capital Markets lifted their price target on Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Monday, December 29th. Mizuho lifted their target price on Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Citizens Jmp upped their target price on shares of Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a research note on Thursday, December 11th. Finally, William Blair raised shares of Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Terns Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $55.56.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.